Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York. more
Time Frame | DCTH | Sector | S&P500 |
---|---|---|---|
1-Week Return | 7.35% | -1.8% | -0.77% |
1-Month Return | 23.19% | -3.48% | 0.71% |
3-Month Return | 23.19% | -7.2% | 8.81% |
6-Month Return | 78.34% | -1.54% | 12.32% |
1-Year Return | 327.53% | 8.39% | 30.57% |
3-Year Return | 52.42% | 6.07% | 29.21% |
5-Year Return | -57.25% | 44.07% | 91.95% |
10-Year Return | -100% | 106.3% | 196.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.58M | 1.65M | 3.56M | 2.72M | 2.06M | [{"date":"2019-12-31","value":44.44,"profit":true},{"date":"2020-12-31","value":46.3,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.48,"profit":true},{"date":"2023-12-31","value":58.09,"profit":true}] |
Cost of Revenue | 719.00K | 640.00K | 671.00K | 686.00K | 635.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.01,"profit":true},{"date":"2021-12-31","value":93.32,"profit":true},{"date":"2022-12-31","value":95.41,"profit":true},{"date":"2023-12-31","value":88.32,"profit":true}] |
Gross Profit | 861.00K | 1.01M | 2.88M | 2.03M | 1.43M | [{"date":"2019-12-31","value":29.85,"profit":true},{"date":"2020-12-31","value":34.88,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.49,"profit":true},{"date":"2023-12-31","value":49.58,"profit":true}] |
Gross Margin | 54.49% | 61.12% | 81.13% | 74.77% | 69.25% | [{"date":"2019-12-31","value":67.17,"profit":true},{"date":"2020-12-31","value":75.34,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":92.17,"profit":true},{"date":"2023-12-31","value":85.36,"profit":true}] |
Operating Expenses | 20.77M | 22.31M | 27.41M | 35.89M | 39.61M | [{"date":"2019-12-31","value":52.43,"profit":true},{"date":"2020-12-31","value":56.32,"profit":true},{"date":"2021-12-31","value":69.21,"profit":true},{"date":"2022-12-31","value":90.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (19.91M) | (21.30M) | (24.53M) | (33.85M) | (38.18M) | [{"date":"2019-12-31","value":-1990800000,"profit":false},{"date":"2020-12-31","value":-2130300000,"profit":false},{"date":"2021-12-31","value":-2453100000,"profit":false},{"date":"2022-12-31","value":-3385300000,"profit":false},{"date":"2023-12-31","value":-3818200000,"profit":false}] |
Total Non-Operating Income/Expense | 6.28M | (3.03M) | (2.30M) | (5.34M) | (11.60M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-48.19,"profit":false},{"date":"2021-12-31","value":-36.67,"profit":false},{"date":"2022-12-31","value":-84.99,"profit":false},{"date":"2023-12-31","value":-184.55,"profit":false}] |
Pre-Tax Income | (8.88M) | (24.16M) | (25.65M) | (36.51M) | (47.68M) | [{"date":"2019-12-31","value":-887900000,"profit":false},{"date":"2020-12-31","value":-2415600000,"profit":false},{"date":"2021-12-31","value":-2564900000,"profit":false},{"date":"2022-12-31","value":-3650800000,"profit":false},{"date":"2023-12-31","value":-4767800000,"profit":false}] |
Income Taxes | 4.75M | 329.00K | 1.11M | 2.65M | (39.90K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":6.93,"profit":true},{"date":"2021-12-31","value":23.34,"profit":true},{"date":"2022-12-31","value":55.92,"profit":true},{"date":"2023-12-31","value":-0.84,"profit":false}] |
Income After Taxes | (13.63M) | (24.48M) | (26.76M) | (39.16M) | (47.64M) | [{"date":"2019-12-31","value":-1362700000,"profit":false},{"date":"2020-12-31","value":-2448500000,"profit":false},{"date":"2021-12-31","value":-2675700000,"profit":false},{"date":"2022-12-31","value":-3916300000,"profit":false},{"date":"2023-12-31","value":-4763810500,"profit":false}] |
Income From Continuous Operations | (8.88M) | (24.16M) | (25.65M) | (36.51M) | (45.01M) | [{"date":"2019-12-31","value":-887900000,"profit":false},{"date":"2020-12-31","value":-2415600000,"profit":false},{"date":"2021-12-31","value":-2564900000,"profit":false},{"date":"2022-12-31","value":-3650800000,"profit":false},{"date":"2023-12-31","value":-4501400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (13.63M) | (24.48M) | (26.76M) | (39.16M) | (47.68M) | [{"date":"2019-12-31","value":-1362700000,"profit":false},{"date":"2020-12-31","value":-2448500000,"profit":false},{"date":"2021-12-31","value":-2675700000,"profit":false},{"date":"2022-12-31","value":-3916300000,"profit":false},{"date":"2023-12-31","value":-4767800000,"profit":false}] |
EPS (Diluted) | 268.70 | (111.73) | (3.63) | (4.12) | (3.06) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-41.58,"profit":false},{"date":"2021-12-31","value":-1.35,"profit":false},{"date":"2022-12-31","value":-1.53,"profit":false},{"date":"2023-12-31","value":-1.14,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DCTH | |
---|---|
Cash Ratio | 0.65 |
Current Ratio | 1.34 |
Quick Ratio | 1.03 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DCTH | |
---|---|
ROA (LTM) | -81.99% |
ROE (LTM) | -478.59% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DCTH | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.73 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.27 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DCTH | |
---|---|
Trailing PE | NM |
Forward PE | 106.38 |
P/S (TTM) | 31.39 |
P/B | 43.50 |
Price/FCF | NM |
EV/R | 15.98 |
EV/Ebitda | NM |
Delcath Systems Inc (DCTH) share price today is $12.27
Yes, Indians can buy shares of Delcath Systems Inc (DCTH) on Vested. To buy Delcath Systems Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DCTH stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Delcath Systems Inc (DCTH) via the Vested app. You can start investing in Delcath Systems Inc (DCTH) with a minimum investment of $1.
You can invest in shares of Delcath Systems Inc (DCTH) via Vested in three simple steps:
The 52-week high price of Delcath Systems Inc (DCTH) is $12.88. The 52-week low price of Delcath Systems Inc (DCTH) is $3.1.
The price-to-earnings (P/E) ratio of Delcath Systems Inc (DCTH) is
The price-to-book (P/B) ratio of Delcath Systems Inc (DCTH) is 43.50
The dividend yield of Delcath Systems Inc (DCTH) is 0.00%
The market capitalization of Delcath Systems Inc (DCTH) is $370.26M
The stock symbol (or ticker) of Delcath Systems Inc is DCTH